Evidence map›Paper›PMID 38673576›Full record

ArticleJournal of clinical medicine2024

Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic.

Pavel Dlouhý, Cyril Mucha, Lenka Mokrá, Matyáš Kuhn, Lenka Hrdlickova, Urs Arnet, Yohance Whiteside

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Pavel DlouhýInfectious Disease Department, Krajská Zdravotní, a.s., 400 11 Ústí nad Labem, Czech Republic.
Cyril MuchaInstitute of General Practice, First Faculty of Medicine, Charles University, 110 00 Prague, Czech Republic.
Lenka MokráInstitute of Biostatistics and Analyses, Ltd., 625 00 Brno, Czech Republic.
Matyáš KuhnInstitute of Biostatistics and Analyses, Ltd., 625 00 Brno, Czech Republic.
Lenka HrdlickovaMSD Czech Republic, 150 00 Prague, Czech Republic.
Urs ArnetCenter for Observational and Real-World Evidence (CORE), MSD Innovation & Development GmbH, 8058 Zürich, Switzerland.ORCID 0009-0007-9592-620X
Yohance WhitesideCenter for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Rahway, NJ 07065, USA.ORCID 0000-0002-7828-3018
Charles University · CZKrajská Zdravotní · CZMerck & Co., Inc., Rahway, NJ, USA (United States) · USO2 Czech Republic (Czechia) · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Czech Republicmolnupiravirreal-world dataSARS-CoV-2treatment of COVID-19

Identifiers

PMID38673576
PMCPMC11051211
OpenAlexW4394879482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.